Reading the tape
NASDAQ: PRME
Prime Medicine, Inc.
Healthcare · Biotechnology
Market Cap
$612.07M
52w High
$6.94
52w Low
$1.11
P/E
-2.51
Volume
2.65M
Outstanding Shares
180.55M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 117.52%Revenue (TTM): 55.28%FCF (TTM): -28.38%
What changed
The stock rose 117.52% over the last year. Revenue grew 55.28% over the trailing twelve months. Operating margin moved from -6,787.36% to -4,498.06%. Free cash flow declined 28.38% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.
What would invalidate this read
Operating margin is at -4,498.06%. Revenue grew 55.28% — this thesis depends on that trajectory holding. Despite the price move, free cash flow fell 28.38%, which is worth watching as a leading indicator of future pressure. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology.
CEOAllan Reine
SectorHealthcare
IndustryBiotechnology
Employees214
IPO dateOct 20, 2022
Valuation
Forward P/E—
EV/EBITDA-2.91
Enterprise value$569.59M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-61.61%
Gross margin-58.05%▼158.05%vs FY2024
Operating margin-4,498.06%▲33.73%vs FY2024
ROE-166.41%▼30.11%vs FY2024
Analyst consensus
RatingBuy
Target price$17.25▲408.85%
5
Buy
4
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.24 · Revenue est $2.33M
View